Contrast-enhanced Ultrasound Evaluation of Chemoembolization

PHASE3CompletedINTERVENTIONAL
Enrollment

131

Participants

Timeline

Start Date

April 30, 2016

Primary Completion Date

December 31, 2021

Study Completion Date

February 1, 2023

Conditions
Hepatocellular CarcinomaChemoembolization, Therapeutic
Interventions
DRUG

Ultrasound contrast agent (Contrast-enhanced ultrasound)

Intravenous injection of ultrasound contrast agent followed by saline flush though an angiocatheter in the arm or hand.

DEVICE

Logiq E9 Scanner (Contrast-enhanced ultrasound)

Ultrasound scanning using a commercial scanner with a C1-5-D broad-spectrum convex transducer followed by a RAB2-5-D broad-spectrum real-time 4D transducer.

Trial Locations (3)

19104

Hospital of the University of Pennsylvania, Philadelphia

19107

Thomas Jefferson University, Philadelphia

92093

University of California, San Diego, La Jolla

Sponsors
All Listed Sponsors
collaborator

University of California, San Diego

OTHER

collaborator

Vanderbilt University Medical Center

OTHER

collaborator

National Institutes of Health (NIH)

NIH

collaborator

Lantheus Medical Imaging

INDUSTRY

collaborator

GE Healthcare

INDUSTRY

collaborator

National Cancer Institute (NCI)

NIH

lead

Sidney Kimmel Cancer Center at Thomas Jefferson University

OTHER